MSI Testing Is Crucial in Colorectal Cancer

Genetic testing – particularly for microsatellite instability (MSI) – is an important step for all patients diagnosed with colorectal cancer (CRC), says Michael J. Overman, M.D., associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center.

Recent findings presented at the 2017 Gastrointestinal Cancers Symposium found that the immunotherapy agent Opdivo (nivolumab) drastically improved response rates and progression-free survival in patients with metastatic CRC who tested positive for MSI. Since the agent is so promising, it is important to identify patients who would benefit from this treatment.